On January 6, 2022, Hoth Therapeutics, Inc. (began dosing to investigate the effect of HT-ALZ on memory, anxiety, and executive function in the APP/PS1+/- mice model after chronic dosing with HT-ALZ. In addition, on January 6, 2022 (the Effective Date), the Company extended the Non-Exclusive Commercial Evaluation License Agreement with Walter Reed Army Institute of Research, a subordinate laboratory of United States Army Medical Research and Materiel Command pursuant to which the term of the agreement was extended for a period of 18 months from the Effective Date.